Hoffmann-la Roche

This study tests a new drug called cevostamab in 20 Chinese patients whose multiple myeloma has come back or stopped responding to treatment. The goal is to see how the drug moves through the body, if it is safe, and if it helps shrink the cancer. Participants will receive the dr…

This early-stage study tests a new medicine called RG6496 in people who carry the gene for Huntington's disease. The main goal is to check if the drug is safe and how the body handles it. About 40 participants will receive a single dose into the spine, with some getting a placebo…

This study tests a drug called alectinib in children and teens with certain rare cancers (solid tumors or brain tumors) that have a specific genetic change called ALK fusion. The tumors have either stopped responding to other treatments or have no good standard options. The goal …

This study tests a drug called glofitamab, alone or with standard chemotherapy, in children and young adults (ages 6 months to under 30) whose B-cell lymphoma has come back or not responded to treatment. The goal is to see if it is safe and can shrink or control the cancer. Parti…

This study offers ongoing access to the medication ocrelizumab for up to 500 people with multiple sclerosis (MS) who were already taking it in a previous study. Researchers will also ask participants about their physical abilities, like walking and daily tasks, to better understa…

This study tests a new medicine called afimkibart in children aged 2 to 17 with moderate to severe ulcerative colitis, a condition causing inflammation and sores in the colon. The goal is to see if the drug can safely reduce symptoms and help children reach remission (feeling bet…

This study tests a new weekly injection called enicepatide in 1600 adults who are overweight or have obesity and also have type 2 diabetes. The goal is to see if it helps with weight loss compared to a placebo over 72 weeks. Participants must be on stable diabetes treatment and h…

This study tests a new drug called Afimkibart for people with moderate to severe rheumatoid arthritis who have not gotten better with or cannot tolerate common treatments like TNF or JAK inhibitors. About 160 participants will receive either the drug or a placebo to see if it red…

This study tests a small implant placed in the eye that releases medication slowly, so patients need treatment only every 24 weeks instead of every 4 weeks. It involves 68 Chinese adults with wet age-related macular degeneration who have already responded to standard injections. …

This study compares two versions of the drug ocrelizumab given as a shot under the skin for people with multiple sclerosis. About 182 participants with relapsing or primary progressive MS will receive either the test or the marketed version. The goal is to see if the new formulat…

This study tests a drug called mosunetuzumab in 30 people with lupus, with or without kidney inflammation. The goal is to see if the drug can put the disease into remission for at least 6 months after treatment ends, without needing ongoing lupus medications (except antimalarials…

This study tests whether a new targeted therapy (divarasib) combined with an immunotherapy (pembrolizumab) works better than standard chemotherapy plus immunotherapy for people with a specific genetic subtype of advanced lung cancer (KRAS G12C mutation). About 600 adults who have…

This study tests a drug called satralizumab to see if it can prevent relapses in people with MOGAD, a rare autoimmune disease that attacks the brain and spinal cord. About 152 participants aged 12 and older will receive either the drug or a placebo. The main goal is to measure ho…

This study tests whether adding an experimental drug (RO7268489) to standard ocrelizumab treatment can slow disability progression in adults with progressive multiple sclerosis. About 360 participants will receive either the drug or a placebo, and those who qualify may continue i…

This study is for people with advanced ER-positive breast cancer that has stopped responding to standard treatments. It tests several different drug combinations to see which ones work best and are safe. About 316 participants will be assigned to different treatment groups based …

This study tests a new drug called RO7790121 (Afimkibart) for people with moderate-to-severe Crohn's disease. The goal is to see if it can reduce symptoms and gut inflammation better than a placebo. About 425 adults who haven't responded well to other treatments will take part. T…

This study tests several different drug combinations in people with metastatic breast cancer that has spread or cannot be removed by surgery. The goal is to see which combinations work best to shrink tumors or slow the disease. About 792 adults with specific breast cancer types w…

This study tests a new medicine called RO7507062 in 70 people with systemic lupus erythematosus (SLE). The goal is to check its safety and how the body processes it. Participants receive the drug as a shot under the skin. This is an early-stage trial, so the main focus is on side…

This study tests a drug called satralizumab in children aged 2 to 11 with a rare disease that attacks the nerves in the eyes and spine (NMOSD). The goal is to see how the drug works in the body and if it can prevent relapses. Only 8 children will take part, and they will receive …

This study provides ongoing treatment with Roche investigational cancer drugs for up to 100 people who were already in a Roche-sponsored study and still need the therapy. Participants will continue their current treatment regimen, and researchers will track side effects and safet…

This study compares a new drug called glofitamab against standard treatments (rituximab plus bendamustine or lenalidomide plus rituximab) in about 182 adults with mantle cell lymphoma that has returned or not responded to prior therapy. Participants must have already tried at lea…

This study tests a new gene therapy called SPK-10001 for people with Huntington's disease. It involves a one-time infusion into specific areas of the brain. The main goals are to check safety and see if it can help control symptoms. About 53 adults with early-stage Huntington's w…

This study tests a small, refillable implant placed in the eye that slowly releases medicine to treat diabetic macular edema (DME), a leading cause of vision loss in people with diabetes. About 634 adults with DME will either get the implant refilled every 24 weeks or receive sta…

This study tests a new drug (RO7771950) combined with two standard treatments for people with advanced HER2-positive breast cancer that has spread or cannot be removed by surgery. The new drug is designed to reach the brain, which is important because this cancer often spreads th…

This study tests whether a combination of two drugs (inavolisib and enzalutamide) works better than standard treatments for men with a specific type of advanced prostate cancer that has stopped responding to hormone therapy. About 100 men will be randomly assigned to receive eith…

This study tests the safety and effectiveness of targeted therapies or immunotherapies in people with metastatic colorectal cancer (cancer that has spread). Participants are assigned to a treatment group based on specific biomarkers found in their tumor. The goal is to see if the…

This study tests a medicine called emicizumab to prevent bleeding episodes in people with Type 3 von Willebrand disease, a severe inherited bleeding disorder. About 75 participants aged 1 month and older will receive regular injections of emicizumab or continue their current stan…

This study tests a once-weekly injection called enicepatide to help people with obesity or overweight lose weight. About 2000 adults who do not have type 2 diabetes will receive either the drug or a placebo for 72 weeks. The main goal is to see how much weight they lose and if th…

This study tests whether adding risdiplam early can improve motor skills in infants under 2 with spinal muscular atrophy who already received gene therapy. About 28 children with two SMN2 gene copies will take risdiplam for 72 weeks. Researchers will track changes in gross motor …

This study tests a drug called obinutuzumab in teens (12-17) and children (5-11) with active lupus nephritis, a serious kidney complication of lupus. The goal is to see if the drug can help the kidneys work better and reduce disease activity. Participants are randomly assigned to…

This study aims to create a blood test that helps doctors quickly diagnose traumatic brain injury (TBI) and predict patient outcomes. Researchers will enroll 2,000 adults with suspected TBI and compare blood biomarkers to standard CT scans and clinical assessments. The goal is to…

This study looks at how satisfied people with lung or liver cancer are with a subcutaneous (under-the-skin) form of the drug atezolizumab. Researchers will also track quality of life, survival, and side effects in about 700 patients receiving the drug as part of their normal care…

This study is for people who carry the Huntington disease gene expansion. Participants visit the clinic once, answer questions about their health and background, and give a blood sample. The blood is tested to find specific genetic markers (SNPs) linked to the disease-causing and…

This early-stage study is testing a new drug called RO7806881 in 128 healthy adults to see if it is safe and how the body processes it. Participants will receive either the drug or a placebo, and researchers will monitor for side effects. The goal is to gather safety information,…

This study looks at how far patients with early-stage HER2-positive breast cancer have to travel for treatment and whether that affects how well they stick to their therapy plan. Researchers will compare patients who travel more versus those who travel less. The goal is to unders…

This study is for people with Type 3 von Willebrand disease, a rare and severe bleeding disorder. Researchers will watch how often bleeding happens and how it affects daily life while participants continue their usual preventive treatment. The goal is to gather real-world informa…

This early-stage study tests an experimental drug called RO7763505 in healthy people and those with stable coronary artery disease. The main goal is to check safety and how the body processes the drug, not to treat the disease. About 196 participants will receive either the drug …

This study is testing a new digital platform designed to help doctors and people with relapsing-remitting multiple sclerosis (MS) better monitor the disease. About 500 participants will use a smartphone app and doctors will use a web-based tool for two years. The goal is to see i…